Induction Chemotherapy Followed by Radiotherapy in Patients with Cervical Lymph Node Metastases from Unknown Primary Carcinoma

被引:2
|
作者
Seol Y.M. [1 ]
Choi Y.J. [1 ]
Lee B.J. [2 ]
Wang S.G. [2 ]
机构
[1] Division of Hematology/Oncology, Department of Internal Medicine, Pusan National University Hospital, Medical Research Institute, Busan
[2] Department of Otolaryngology, Pusan National University Hospital, Medical Research Institute, Busan
关键词
Head and neck cancer; Induction chemotherapy; Lymph node metastasis; Unknown primary;
D O I
10.1007/s12070-014-0773-8
中图分类号
学科分类号
摘要
Cervical metastases from unknown primary tumors are rare and no clear therapeutic options are available. This study was performed to assess the efficacy and safety profiles of induction chemotherapy followed radiotherapy in patients with cervical lymph node metastases from unknown primary cancer. Patients with histological diagnosis of cervical lymph-node metastasis from carcinoma with an unknown primary cancer underwent induction chemotherapy followed by radiotherapy. All patients had squamous cell carcinoma. Induction chemotherapy consisted of 3–4 cycles every 3 weeks of docetaxel (day 1.70 mg/m2) and cisplatin (day 1.75 mg/m2). Radiation therapy (RT) was started with in 10 weeks of the last cycle of chemotherapy, and it was administered 5 days per week. It was given in daily fractions of (1.8) Grays (Gy) of 2 Gy and the total dose to the primary tumor was 70–74 Gy. Neck dissection was reserved for residual disease after definitive radiotherapy. Overall survival, recurrent free survival, and locoregional control were calculated using the Kaplan–Meier method. Twenty one patients with an unknown primary cancer underwent induction chemotherapy and radiotherapy. After induction chemotherapy, 6 patients achieved CR and 8 patients achieved PR. The overall response rate after radiation, was 90.4 % (19 of 21 patients). Neutropenia and infection were the most common grade 3–4 adverse event during induction chemotherapy. Mucositis and dermatitis were the most common grade 3–4 toxicities during radiotherapy. With a median follow-up of 50.6 months, the estimated 2 years OS rates were 71 ± 6 %, respectively. The median OS was 42 months (95 % confidence interval CI 8–65 months). The recurrent-free survival rate at 2 years was 57 %, respectively. In the patients with responder to induction chemotherapy, superior relapse free survival and overall survival rate observed. No occurrence of primary cancer was observed during the follow-up period. Induction chemotherapy followed RT for unknown primarycancer has provided good overall and disease-free survival in all the patients with anacceptable rate of complications. The use of induction chemotherapy and radiationtherapy for more advanced disease led to good clinical results with reasonable toxicities. © 2014, Association of Otolaryngologists of India.
引用
收藏
页码:74 / 78
页数:4
相关论文
共 50 条
  • [21] Tumor control of cervical lymph node metastases of unknown primary origin: the impact of the radiotherapy target volume
    Jos M. J. A. A. Straetmans
    Marijn Stuut
    Sanne Wagemakers
    Frank Hoebers
    Johannes H. A. M. Kaanders
    Ernst Jan M. Speel
    Willem J. G. Melchers
    Piet Slootweg
    Bernd Kremer
    Martin Lacko
    Robert P. Takes
    European Archives of Oto-Rhino-Laryngology, 2020, 277 : 1753 - 1761
  • [22] Cervical Squamous Cell Lymph Node Metastases from an Unknown Primary Site: Survival and Patterns of Recurrence after Radiotherapy
    Gani, Cihan
    Eckert, Franziska
    Mueller, Arndt-Christian
    Mauz, Paul-Stefan
    Thiericke, John
    Bamberg, Michael
    Weinmann, Martin
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 173 - 180
  • [23] Uni or bilateral Irradiation in Cervical Lymph Node Metastases of Unknown Primary?
    Thariat, J. O.
    Troussier, I.
    Sun, X. S.
    Salleron, J.
    Petit, C.
    Pflumio, C.
    Arnaud, B.
    Stephanie, S. V.
    Castelli, J.
    Miroir, J.
    Krengli, M.
    Giraud, P.
    Khalifa, J.
    Dore, M.
    Blanchard, N.
    Coutte, A.
    Sumodhee, S.
    Calugaru, V.
    Tao, Y.
    Dupin, C.
    Pointreau, Y.
    Patel, S. H.
    Rehalia-Blanchard, A.
    Catteau, L.
    Bensadoun, R. J.
    Roth, V.
    Christophe, F. Jean
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E367 - E368
  • [24] Neck lymph node metastases from unknown primary
    Arosio, Alberto Daniele
    Pignataro, Lorenzo
    Gaini, Renato Maria
    Garavello, Werner
    CANCER TREATMENT REVIEWS, 2017, 53 : 1 - 9
  • [25] Cervical lymph node metastases from unknown primary cancer treated by surgery and radiation
    Mueller-Beffa, L
    Amsler, B
    Landmann, C
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 : 126 - 126
  • [26] Cytologic evaluation of cervical lymph node metastases from cancers of unknown primary origin
    Pusztaszeri, Marc P.
    Faquin, William C.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2015, 32 (01) : 32 - 41
  • [27] Chemoradiation as a Definitive Treatment for Cervical Lymph Node Metastases from Unknown Primary Cancer
    Kaizu, Hisashi
    Ogino, Ichiro
    Hata, Masaharu
    Oba, Mari S.
    Shiono, Osamu
    Komatsu, Masanori
    Inoue, Tomio
    ANTICANCER RESEARCH, 2013, 33 (11) : 5187 - 5192
  • [28] Cervical lymph node metastases of unknown primaries. With special emphasis on radiotherapy
    Haussmann, Jan
    Budach, Wilfried
    ONKOLOGE, 2017, 23 (12): : 986 - 992
  • [29] Treatment Outcome of Metastatic Carcinoma of Cervical Lymph Node from an Unknown Primary
    Kim, Kyubo
    Chie, Eui Kyu
    Wu, Hong-Gyun
    Kim, Kwang Hyun
    Sung, Myung-Whun
    Heo, Dae Seog
    Park, Charn Il
    RADIATION ONCOLOGY JOURNAL, 2005, 23 (03): : 137 - 142
  • [30] STEREOTACTIC RADIOTHERAPY IN PATIENTS WITH LYMPH NODE METASTASES FROM PROSTATE CARCINOMA
    Cagna, Emanuela
    Serafini, Flavia
    Barsacchi, Lucia
    Frigerio, Milena
    Bianchi, Ernestina
    Laudati, Antonio
    Pittoni, Patrizia
    Prina, Morena
    Scandolaro, Luciano
    Berlusconi, Chiara
    Gelosa, Stefania
    Lattuada, Paola
    ANTICANCER RESEARCH, 2016, 36 (05) : 2588 - 2589